ATE208206T1 - Immunologische verbesserung mit intermittierender interleukin-2 therapie - Google Patents

Immunologische verbesserung mit intermittierender interleukin-2 therapie

Info

Publication number
ATE208206T1
ATE208206T1 AT94920673T AT94920673T ATE208206T1 AT E208206 T1 ATE208206 T1 AT E208206T1 AT 94920673 T AT94920673 T AT 94920673T AT 94920673 T AT94920673 T AT 94920673T AT E208206 T1 ATE208206 T1 AT E208206T1
Authority
AT
Austria
Prior art keywords
therapy
period
intermittent
infusions
interleukin
Prior art date
Application number
AT94920673T
Other languages
English (en)
Inventor
H Clifford Lane
Joseph A Kovacs
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE208206T1 publication Critical patent/ATE208206T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT94920673T 1993-05-19 1994-05-19 Immunologische verbesserung mit intermittierender interleukin-2 therapie ATE208206T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/063,315 US5419900A (en) 1993-05-19 1993-05-19 Immunologic enhancement with intermittent interleukin-2 therapy
PCT/US1994/005397 WO1994026293A1 (en) 1993-05-19 1994-05-19 Immunologic enhancement with intermittent interleukin-2 therapy

Publications (1)

Publication Number Publication Date
ATE208206T1 true ATE208206T1 (de) 2001-11-15

Family

ID=22048393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920673T ATE208206T1 (de) 1993-05-19 1994-05-19 Immunologische verbesserung mit intermittierender interleukin-2 therapie

Country Status (11)

Country Link
US (3) US5419900A (de)
EP (1) EP0702560B1 (de)
JP (1) JP4275193B2 (de)
AT (1) ATE208206T1 (de)
AU (1) AU691504B2 (de)
CA (1) CA2163219A1 (de)
DE (1) DE69428992T2 (de)
DK (1) DK0702560T3 (de)
ES (1) ES2167370T3 (de)
PT (1) PT702560E (de)
WO (1) WO1994026293A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
WO1997014812A2 (en) * 1995-10-16 1997-04-24 Chiron Corporation Method of screening for factors that modulate gene expression
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
EP1034003A4 (de) * 1997-11-24 2004-07-14 Johnson T Wong Methoden zur behandlung von hiv oder anderer infektionen unter verwendung eines t-zell-aktivators oder eines viralen aktivators und einer antiretroviralen kombinationstherapie
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
US6602705B1 (en) * 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
FR2813793B1 (fr) * 2000-09-08 2003-01-24 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20030198621A1 (en) * 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1476180A4 (de) * 2001-08-13 2005-04-20 Univ Southern California Interleukin-2 mutanten mit verringerter toxizität
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AU2002316578A1 (en) * 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
EP1676132B1 (de) 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Kombination von Chemotherapie und Applikation von Glioma-Antigen-gepulsten dendritischen Zellen zur Glioma Behandlung
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP2328923B1 (de) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133-epitope
WO2010129895A2 (en) 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Cd133 epitopes
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
ES2719495T3 (es) 2012-05-07 2019-07-10 Dartmouth College Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
EP3204119B1 (de) 2014-10-09 2021-06-09 Dana-Farber Cancer Institute, Inc. Mehrfach-variabler il-2-dosierungsplan zur behandlung von immunerkrankungen
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
US4868157A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4866157A (en) * 1987-11-10 1989-09-12 Sugio Otani Thermosetting aromatic resin composition
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
JP2552047B2 (ja) 1990-01-26 1996-11-06 ワシントン リサーチ ファウンデーション 悪性腫瘍の検査方法
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy

Also Published As

Publication number Publication date
PT702560E (pt) 2002-04-29
WO1994026293A1 (en) 1994-11-24
JPH09500362A (ja) 1997-01-14
JP4275193B2 (ja) 2009-06-10
AU7137794A (en) 1994-12-12
DK0702560T3 (da) 2002-02-25
US6548055B1 (en) 2003-04-15
DE69428992T2 (de) 2002-08-14
EP0702560B1 (de) 2001-11-07
DE69428992D1 (de) 2001-12-13
AU691504B2 (en) 1998-05-21
ES2167370T3 (es) 2002-05-16
CA2163219A1 (en) 1994-11-24
US5419900A (en) 1995-05-30
EP0702560A1 (de) 1996-03-27
US6190656B1 (en) 2001-02-20

Similar Documents

Publication Publication Date Title
DE69428992T2 (de) Immunologische verbesserung mit intermittierender interleukin-2 therapie
Teodorczyk-Injeyan et al. Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression.
ES2156852T3 (es) Citoquina mamifera, il-11.
DE69333580D1 (de) Immunregulation über die cd28-route
IL69731A0 (en) Homogeneous human interleukin 2,its preparation and pharmaceutical compositions containing it
DK0626177T3 (da) Ernæring til personer inficeret med humant immundefekt-virus
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
IT8521468A0 (it) Procedimento per ottenere interferon leucocitario alfa-2dell'uomo.
FR2662942B1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae.
Guerin et al. Suppression of HLA class II expression on thyrocytes by interferon-alpha 1
RU94045248A (ru) Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo
IT1237435B (it) Farmaco attivo nel ripristino della plasticita' neuronale.
Lane et al. Immunologic enhancement with intermittent interleukin-2 therapy
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
Lein Immune-based therapies
LAKE et al. T-cell replacing factor activity of recombinant-derived interleukin-2 requires gamma-interferon
Kurpisz et al. Blast transformation of lymphocytes induced by spermatozoa obtained from spermatocoele
YU4792A (sh) Postupak gajenja tumornih infiltirajućih limfocita
SARMÁNY Individual Differences in the Estimation of Short-Time Intervals during Circadian Rhythm
Bogdahn et al. Interferon-beta in patients with low-grade astrocytomas--a phase I study.
Polmar et al. Pharmacological Modulation of Immunoregulatory Lymphocyte Functions: The Adenosine Immunoregulatory System
Elwood IL-2 helping rebuild the immune system in HIV infection
MY106292A (en) (alpha)-adrenergic receptor antagonists.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification